A5050987906- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- CAR-T cell therapy research
- Multiple Myeloma Research and Treatments
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Immune Cell Function and Interaction
- Lymphoma Diagnosis and Treatment
- Polyomavirus and related diseases
- T-cell and B-cell Immunology
- Neutropenia and Cancer Infections
- Cancer Treatment and Pharmacology
- Cytomegalovirus and herpesvirus research
- Immunodeficiency and Autoimmune Disorders
- Renal Transplantation Outcomes and Treatments
- Childhood Cancer Survivors' Quality of Life
- Mesenchymal stem cell research
- Protein Degradation and Inhibitors
- Eosinophilic Disorders and Syndromes
- Virus-based gene therapy research
- Transplantation: Methods and Outcomes
- Viral-associated cancers and disorders
- Hemoglobinopathies and Related Disorders
Inserm
2016-2025
Lille Inflammation Research International Center
2016-2025
Centre Hospitalier Universitaire de Lille
2016-2025
Université de Lille
2016-2025
Institute for Translational Research in Inflammation
2019-2024
Lille’s Cardiology Hospital
2007-2024
Catalan Society of Family and Community Medicine
2024
Hôpital Claude Huriez
2014-2023
University Medical Center Hamburg-Eppendorf
2023
Universität Hamburg
2023
Idecabtagene vicleucel (ide-cel, also called bb2121), a B-cell maturation antigen–directed chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity with expected CAR toxic effects in patients relapsed and refractory multiple myeloma.
Sinusoidal obstruction syndrome, also known as veno-occlusive disease (SOS/VOD), is a potentially life threatening complication that can develop after hematopoietic cell transplantation. Although SOS/VOD progressively resolves within few weeks in most patients, the severe forms result multi-organ dysfunction and are associated with high mortality rate (>80%). Therefore, careful attention must be paid to allow an early detection of SOS/VOD, particularly drugs have now proven effective...
Numbers of Hematopoietic cell transplantation (HCT) in Europe and collaborating countries continues to rise with 48,512 HCT 43,581 patients, comprising 19,798 (41%) allogeneic 28,714 (59%) autologous, reported by 700 centers 51 during 2019. Main indications were myeloid malignancies 10,764 (25%), lymphoid 27,895 (64%), nonmalignant disorders 3173 (7%). A marked growth CAR-T cellular therapies from 151 2017 1134 patients 2019 is observed. This year's analyses focus on changes over 30 years....
Chimeric antigen receptor (CAR) T cells are a novel class of anti-cancer therapy in which autologous or allogeneic engineered to express CAR targeting membrane antigen. In Europe, tisagenlecleucel (Kymriah™) is approved for the treatment refractory/relapsed acute lymphoblastic leukemia children and young adults as well relapsed/refractory diffuse large B-cell lymphoma, while axicabtagene ciloleucel (Yescarta™) high-grade lymphoma primary mediastinal lymphoma. Both agents genetically CD19....
Aggressive T-cell lymphomas (ATCLs) represent 10% to 15% of non-Hodgkin's (NHLs) in adults. ATCLs show a worse prognosis than B-cell lymphomas.On behalf the Société Française de Greffe Moëlle et Thérapie Cellulaire, we conducted retrospective analysis including 77 ATCL patients who underwent allogeneic stem-cell transplantation (alloSCT).The different diagnosis included anaplastic large-cell lymphoma (ALCL; n = 27), peripheral not otherwise specified (PTCL-NOS; angioimmunoblastic (AITL; 11),...
Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade lymphoma mantle cell lymphoma. Products other diseases such as multiple myeloma follicular are likely to be by the European Medicines Agency near future.The Society Blood Marrow Transplantation (EBMT)-Joint Accreditation Committee of ISCT EBMT (JACIE) Haematology Association...
For over two decades, the EBMT has updated recommendations on indications for haematopoietic cell transplantation (HCT) practice based clinical and scientific developments in field. This is eighth special report HCT haematological diseases, solid tumours immune disorders. Our aim to provide general guidance according prevailing countries centres. In order inform patient decisions, these must be considered conjunction with risk of disease, procedure non-transplant strategies, including...
Abstract Hematopoietic-cell transplantation (HCT) is widely used for acquired and congenital disorders of the hematopoietic system. Number transplants performed in Europe associated countries continues to rise with 47,468 HCT 42,901 patients [19,630 allogeneic (41%) 27,838 autologous (59%)] reported by 701 centers 50 2018. Main indications were myeloid malignancies 10,679 (25%; 97% allogeneic), lymphoid 27,318 (64%; 20% solid tumors 1625 (4%; 2.9% nonmalignant 3063 (7%; 81% allogeneic). This...
Hematopoietic cell transplantation (HCT) is widely used for acquired and congenital disorders of the hematopoietic system. Number transplants done in Europe associated countries continues to rise with 45,418 HCT 41,100 patients [(17,155 allogeneic (42%) 23,945 autologous (58%)] reported by 683 centers 50 2017. Main indications were myeloid malignancies 10,147 (25%; 96% allogeneic), lymphoid 26,488 (64%; 19% solid tumors 1,607 (3.9%; 2% nonmalignant 2,667 (7%; 81% allogeneic). Trends donor...
Abstract We performed a study to find out how advances in modern medicine have improved the mortality risk of allogeneic stem cell transplantation. analyzed major transplantation outcome parameters adult patients on European Society for Blood and Marrow Transplantation (EBMT) registry who had hematologic malignancies received transplants from matched sibling donors. multivariate analyses using Cox proportional-hazards model including known factors nonrelapse matched-pairs analysis....
Abstract The recently described vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is caused by mutations in UBA1. Patients with VEXAS display late-onset autoinflammatory symptoms, usually refractory to treatment, and hematologic abnormalities. identification of an easily-accessible specific marker (UBA1 mutations) particular interest as it allows the convergence various inflammatory hematological symptoms a unique clinico-biological entity gives opportunity design...
Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory (R/R) follicular lymphoma (FL). Approval was supported by the phase 2, multicenter, single-arm ZUMA-5 study of axi-cel patients with R/R indolent non-Hodgkin (iNHL; N = 104), including FL and marginal zone (MZL). In primary analysis (median follow-up, 17.5 months), overall response rate (ORR) 92% (complete rate, 74%). Here, we report long-term outcomes...